These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 15733528)
1. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form. Prantera C; Bellinvia S Dig Liver Dis; 2005 Feb; 37(2):135-6. PubMed ID: 15733528 [No Abstract] [Full Text] [Related]
2. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609 [TBL] [Abstract][Full Text] [Related]
3. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584 [TBL] [Abstract][Full Text] [Related]
4. Current treatment for prevention of relapse and recurrence in Crohn's disease. Prantera C; Scribano ML Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572 [TBL] [Abstract][Full Text] [Related]
5. Can postoperative relapse of Crohn's disease be prevented? Dumois RA; Herrera JL Am J Gastroenterol; 2001 Jan; 96(1):249. PubMed ID: 11197264 [No Abstract] [Full Text] [Related]
6. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. Feagan BG Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385 [No Abstract] [Full Text] [Related]
7. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656 [TBL] [Abstract][Full Text] [Related]
8. Mesalamine derivatives in the treatment of Crohn's disease. Harrell LE; Hanauer SB Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540 [TBL] [Abstract][Full Text] [Related]
15. Mesalamine and relapse prevention in Crohn's disease. Cottone M; Cammà C Gastroenterology; 2000 Aug; 119(2):597. PubMed ID: 10960274 [No Abstract] [Full Text] [Related]
16. A comparison of budesonide and mesalamine for active Crohn's disease. Lowry PW; Sandborn WJ Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523 [No Abstract] [Full Text] [Related]
17. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143 [TBL] [Abstract][Full Text] [Related]
18. [Mesalazine is without clinical effect in patients with Crohn disease]. Munck LK Ugeskr Laeger; 2005 Jan; 167(3):302-3. PubMed ID: 15704804 [No Abstract] [Full Text] [Related]
19. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature]. Neĭman KP; Rumiantsev VG Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844 [No Abstract] [Full Text] [Related]
20. [Mesalamine in the treatment of Crohn disease?]. Nielsen OH; Thomsen OO Ugeskr Laeger; 2005 Apr; 167(15):1656-7. PubMed ID: 15892345 [No Abstract] [Full Text] [Related] [Next] [New Search]